Clinical trials: Ovary Disease
Breast Cancer, Ovarian Neoplasm
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
Paclitaxel, a widely used chemotherapeutic agent, is associated with several well-known side effects including neuropathy (weakness, numbness and pain) and generalized body aches.
- Conditions
- Breast Cancer, Ovarian Neoplasm, Pain
- Trial name
- NCT01821833
- Testing
- Omega-3 fatty acid, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- New Mexico Cancer Research Alliance
Ovarian Cancer, Prostate Cancer
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
This is a multi-centre, prospective, non-interventional study. The study will enrol about 860 Chinese cancer patients from around 56 sites.
- Trial name
- NCT04560452
- Where
- 37 sites in China
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied
- Trial name
- NCT05410015
- Testing
- Normal clinical treatment without intervention
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer
The combination of paclitaxel and carboplatin in a three weeks schedule has emerged as the current standard approach for the adjuvant treatment of ovarian cancer.
- Trial name
- NCT00170664
- Testing
- Paclitaxel, Carboplatin
- Where
- Germany
- Volunteers
- 129 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00939809
- Testing
- Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis
- Where
- 16 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women
RATIONALE: Screening tests may help doctors detect ovarian cancer early when the survival is much more encouraging. It is not yet known whether a CA125-based or ultrasound strategy is more effective in detecting ovarian cancer…
- Trial name
- UKCTOCS (NCT00058032)
- Testing
- screening questionnaire administration, annual screening
- Volunteers
- 202,638 people, healthy volunteers welcome
- Sponsor
- University College, London
Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors
Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.
Granulosa Cell ovarian carcinoma is an infrequent subtype of neoplasia well differentiated from epithelial tumors. They account for 5% of all ovarian malignancies and, with an incidence of 0.4-1.2 cases per 100000 habitants, is…
- Trial name
- Greko II (NCT02101684)
- Testing
- Orteronel 300mg BID
- Where
- 9 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Grupo Español de Tumores Huérfanos e Infrecuentes
Ovarian Carcinoma
Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy.
- Trial name
- IFFaLCCO (NCT02297958)
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Rennes University Hospital
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00096200
- Testing
- Carboplatin, Paclitaxel, Sorafenib Tosylate
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Carcinomatosis
Peritoneal Carcinomatosis Extent Evaluation: Radiologic, Laparoscopic and Pathologic.
pathologically proved ovarian cancer patients that underwent contrast enhanced abdomino-pelvic CT and diagnostic laparoscopy before cytoreductive surgery (CRS) will be included in the study.
- Trial name
- NCT03798132
- Testing
- laparoscopy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Shimaa Abdalla Ahmed
Ovarian Cancer
The Effect of TRA-8 on Ovarian Cancer Tissue
The goal of this study is to determine the apoptosis-inducing efficacy of TRA-8 in patient ovarian cancer tissues using a tissue slice technology.
- Trial name
- NCT00711932
- Where
- United States
- Volunteers
- 478 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Cancer Lung, Metastatic Ovarian Cancer
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
This is a clinical trial category C as this is a first in man trial with an unapproved investigational product. Nevertheless the risk is considered low due to the low dose ≤ 10μg.
- Trial name
- NCT03242993
- Testing
- [18F]-AzaFol, folarell
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University of Lausanne Hospitals
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Ovarian Cancer
Safety in Ovarian Cancer for Average-Risk Women - Analysis
This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women.
- Trial name
- SOARA (NCT07872644)
- Testing
- Blood-Based Ovarian Cancer Screening Test
- Where
- 2 sites in United States
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Mercy BioAnalytics, Inc.
Male Breast Cancer, Recurrent Breast Cancer
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of AFP464 in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT00348699
- Testing
- AFP464, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other…
- Trial name
- NCT03857087
- Testing
- Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients
This study investigates an innovative treatment for recurrent ovarian cancer exploiting ex vivo-generated allogeneic natural killer (NK) cells with or without preceding non-myeloablative conditioning chemotherapy.
- Conditions
- Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- INTRO (NCT03539406)
- Testing
- UCB-NK cells, Chemotherapy
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Radboud University Medical Center
Endometrial Cancer, Ovarian Cancer
Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project
Follow-up of cancer patients accounts for a substantial part of outpatient activity, and alternative models of care are developing.
- Conditions
- Endometrial Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- NCT01691144
- Where
- 2 sites in Norway
- Volunteers
- 239 people
- Sponsor
- University of Oslo
Ovarian Cancer, Fallopian Tube Cancer
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00343044
- Testing
- Topotecan, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
PCOS, NAFLD
Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
This study was planned to examine the prevalence of vitamin D insufficiency, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and their relationship with each other and the nutritional status of individuals with…
- Trial name
- NCT05843955
- Testing
- Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Hacettepe University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.